Invention Grant
- Patent Title: Fused tricyclic inhibitors of mammalian target of rapamycin
- Patent Title (中): 雷帕霉素哺乳动物靶标的融合三环抑制剂
-
Application No.: US13876192Application Date: 2011-09-26
-
Publication No.: US08927562B2Publication Date: 2015-01-06
- Inventor: Zhaoyang Meng , Panduranga Adulla Reddy , M. Arshad Siddiqui
- Applicant: Zhaoyang Meng , Panduranga Adulla Reddy , M. Arshad Siddiqui
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Richard S. Parr; Laura M. Ginkel
- International Application: PCT/US2011/053201 WO 20110926
- International Announcement: WO2012/047570 WO 20120412
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D487/14 ; C07D495/14 ; C07D487/04
Abstract:
This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.
Public/Granted literature
- US20130281474A1 FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN Public/Granted day:2013-10-24
Information query
IPC分类:
